Clinical trials: Head and Neck Cancer Patients
Head And Neck Cancer
Testing Accountability in Patient Adherence
The goal of this research study is to look for factors that influence whether or not head and neck cancer patients follow the swallowing exercises that they are asked to perform while receiving radiation treatment.
- Trial name
- NCT01844557
- Testing
- Swallowing Exercises, Symptom Inventory, Questionnaires
- Where
- United States
- Volunteers
- 225 people
- Sponsor
- M.D. Anderson Cancer Center
Head and Neck Squamous Cell Carcinoma, Oral Mucositis
MIT-001 for Prevention of CCRT-Induced OM in HNSCC Patients
The proposed study in patients with previously untreated locally advanced head and neck squamous cell carcinoma (HNSCC) is designed to evaluate the efficacy and safety of three different doses of MIT-001 compared to the placebo…
- Trial name
- MIT-001 (NCT04651634)
- Testing
- MIT-001 plus CCRT
- Where
- 16 sites in United States, South Korea
- Volunteers
- 60 people
- Sponsor
- MitoImmune Therapeutics
HER2-positive Solid Tumors, HER2-positive Breast Cancer
A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors
A first-in-human study using BDC-1001 as a single agent and in combination with nivolumab in HER2 expressing advanced malignancies
- Conditions
- HER2-positive Solid Tumors, HER2-positive Breast Cancer, HER2-positive Colorectal Cancer, HER2-positive Gastroesophageal Cancer
- Trial name
- NCT04278144
- Testing
- BDC-1001, Nivolumab
- Where
- 21 sites in United States, France and 2 more
- Volunteers
- 175 people
- Sponsor
- Bolt Biotherapeutics, Inc.
Thyroid Cancer
rhTSH-Thyroid Ablation With 1850 MBq of 131I
Most patients with differentiated thyroid carcinoma (DTC) are treated with therapeutic doses of radioiodine (131I) after initial surgery (total or near total thyroidectomy), aimed to destroy microscopic residual normal or tumoral…
- Trial name
- NCT00454077
- Testing
- radioiodine therapy after rhTSH
- Where
- Italy
- Volunteers
- 72 people
- Sponsor
- University of Siena
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
Study of ALE.C04 in Patients With Head and Neck Cancer
The purpose of this study is to evaluate the safety profile of ALE.C04 monotherapy and in combination with pembrolizumab, to characterize pharmacokinetics profile of ALE.C04, recommended Phase II dose (RP2D) for ALE.C04 in…
- Trial name
- NCT06054477
- Testing
- ALE.C04, Pembrolizumab
- Where
- 22 sites in United States, Canada and 6 more
- Volunteers
- 21 people
- Sponsor
- Alentis Therapeutics AG
Brain Tumors, Central Nervous System Tumors
Electroacupuncture in Treating Delayed Nausea and Vomiting in Patients Receiving Chemotherapy For Newly Diagnosed Childhood Sarcoma, Neuroblastoma, Nasopharyngeal Cancer, Germ Cell Tumors, or Hodgkin Lymphoma
RATIONALE: Electroacupuncture may help to reduce or prevent delayed nausea and vomiting in patients treated with chemotherapy. PURPOSE: This randomized clinical trial is studying the effectiveness of electroacupuncture in…
- Conditions
- Brain Tumors, Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor
- Trial name
- NCT00040911
- Testing
- electroacupuncture therapy, quality-of-life assessment
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Children's Oncology Group
The Families or Next of Kin of Patients Treated at MSKCC for Non-cutaneous Squamous Cell Carcinomas of the, Upper Aerodigestive Tract
Improving End of Life Care in Head and Neck Cancer
The purpose of this study is to improve the quality of care provided for head and neck cancer patients. By better understanding the end of life experiences of dying patients and their families, the investigators hope to better…
- Trial name
- NCT01632969
- Testing
- The The Family Assessment of Treatment at the End of life (FATE ) survey
- Where
- United States
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- Memorial Sloan Kettering Cancer Center
Head and Neck Cancer
Imatinib Mesylate in Treating Patients With Salivary Gland Cancer
RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. PURPOSE: Phase II trial to study the effectiveness of imatinib mesylate in treating patients who have…
- Trial name
- NCT00045669
- Testing
- imatinib mesylate
- Where
- 15 sites in United States, Canada
- Volunteers
- 16 people
- Sponsor
- University Health Network, Toronto
Head and Neck Cancer (H&Amp;Amp;N), Radiation-induced Oral Mucositis
Mouthwash Temperature and Oral Mucositis in Head and Neck Radiotherapy
This single-center randomized controlled trial evaluates the effects of cold (15-20°C) versus room-temperature (30-35°C) water gargling on oral mucositis severity, pain, and comfort in patients with head and neck cancer…
- Conditions
- Head and Neck Cancer (H&Amp;Amp;N), Radiation-induced Oral Mucositis, Supportive Care, Nursing Interventions
- Trial name
- CoolRinseHNC (NCT07252557)
- Testing
- Water Rinse at Different Temperatures
- Where
- Taiwan
- Volunteers
- 200 people
- Sponsor
- Chung Shan Medical University
Head and Neck Cancer, Oral Complications
Oral Mucositis in Patients Receiving Radiation Therapy for Cancer of the Mouth, Pharynx, or Larynx
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Giving radiation therapy at different times of the day may affect the chance of developing side effects such as mucositis.
- Trial name
- NCT00004234
- Testing
- management of therapy complications, radiation therapy
- Where
- 14 sites in Canada
- Sponsor
- NCIC Clinical Trials Group
Metastatic Cancer, Solid Tumor
Sym021 in Combination With Either Sym022 or Sym023 or Sym023 and Irinotecan in Patients With Recurrent Advanced Selected Solid Tumor Malignancies
The study will evaluate the preliminary efficacy of 3 combinations (Sym021+Sym022, Sym021+Sym023 and Sym021+Sym023+irinotecan) in patients with biliary tract carcinomas (BTC) and with esophageal squamous cell carcinoma (ESCC) by…
- Trial name
- NCT04641871
- Testing
- Sym021, Sym022, Sym023
- Where
- 17 sites in United States, Canada and 2 more
- Volunteers
- 78 people
- Sponsor
- Symphogen A/S
Head and Neck Cancer, Squamous Cell Carcinoma
Cetuximab in Head and Neck Cancer Patients
This clinical trial is for participants with head and neck squamous cell carcinoma who are scheduled to have their tumor surgically removed.
- Trial name
- NCT03769311
- Testing
- Cetuximab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Wisconsin, Madison
Hepatocellular Carcinoma, Esophageal Cancer
PLA for HCC and Esophageal ca Serum
The primary goal of this study is to quantify the biomarkers of pre-radiation therapy(RT), during-RT, and post-RT serum samples from hepatocellular carcinoma (HCC) and esophageal cancer patients undergoing definitive or…
- Trial name
- NCT01957241
- Where
- Taiwan
- Volunteers
- 164 people
- Sponsor
- National Taiwan University Hospital
Head and Neck Cancer
Surgery and Radiation Therapy With or Without Interleukin-2 in Treating Patients With Cancer of the Mouth or Oropharynx
RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill cancer cells of the mouth or oropharynx. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00002702
- Testing
- aldesleukin, adjuvant therapy, conventional surgery
- Where
- 7 sites in Italy
- Volunteers
- 260 people
- Sponsor
- European Institute of Oncology
Oral Cancer , Oral Squamous Cell Carcinoma, Oral Cavity Cancer
Immunohistochemical Expression of EGFR in the Patients Having Oral Squamous Cell Carcinoma
Oral squamous cell carcinoma (OSCC) is one of the top 10 most common malignancies worldwide. Oral squamous cell carcinoma forms a major health problem in many countries.
- Trial name
- EGFR (NCT06606301)
- Testing
- BioSB EGFR antibody
- Where
- Pakistan
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Combined Military Hospital, Pakistan
Head and Neck Cancer, Unspecified Adult Solid Tumor, Protocol Specific
L-778,123 in Treating Patients With Recurrent or Refractory Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of L-778,123 in treating patients with recurrent or…
- Trial name
- NCT00003430
- Testing
- L-778,123
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Metastatic Melanoma, Head and Neck Squamous Cell Carcinoma
GB1211 and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma
The purpose of this study is to determine the objective response of GB1211 and pembrolizumab versus pembrolizumab and placebo in patients with advance metastatic melanoma or head and neck squamous cell carcinoma.
- Trial name
- NCT05913388
- Testing
- GB1211, Pembrolizumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Providence Health & Services
Esophageal Cancer
Chemotherapeutic Trial With Gemcitabine, Cisplatin, 5-FU and Folinic Acid in Esophageal Cancer
This multicenter open labeled phase 2 trial examines the efficacy of a combination of Gemcitabine 1000 mg/m2 (30 min), Cisplatin 30 mg/m2 (90 min), Folinic Acid 200 mg/m2 (30 min) and 5-FU 750 mg/m2 (24h CI) all given day 1,8 q…
- Trial name
- CONKO-101 (NCT00759226)
- Testing
- Gemcitabine, Cisplatin, 5-FU
- Where
- Germany
- Volunteers
- 92 people
- Sponsor
- CONKO-Studiengruppe
Esophageal Cancer
Continuous Endostar Infusion Combined With Radiotherapy in Esophageal Cancer Patients
This study is to explore the clinical efficacy of continuous Endostar infusion combined with radiotherapy in esophageal cancer patients.
- Trial name
- NCT01368419
- Testing
- Endostar, Radiotherapy
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
Solid Tumors
A Dose Escalation Study of Adavosertib(MK1775) in Combination With 5-FU or 5-FU/CDDP in Patients With Advanced Solid Tumor (1775-005
The study evaluates safety of adavosertib in monotherapy, and in combination with 5-Fluorouracil (5-FU) alone or with 5-FU/cis-diamminedichloroplatinum (CDDP) in Japanese participants with solid tumor.
- Trial name
- NCT01047007
- Testing
- adavosertib 20 mg, 5-FU 1000 mg/m^2/day, CDDP
- Volunteers
- 11 people
- Sponsor
- Merck Sharp & Dohme LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.